



## Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017

**Lund, Sweden, 21 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, presents the company at Redeye Life Science Seminar on Friday 24 November (10:15 am CET) at Haymarket in Stockholm, Sweden. The presentation can be followed in real-time at [www.redeye.se](http://www.redeye.se).**

The presentation will also be accessible after the event at [www.redeye.se](http://www.redeye.se) and on the company page at Redeye Universe ([www.redeye.se/company/alligator-bioscience](http://www.redeye.se/company/alligator-bioscience)).

### **For further information:**

Cecilia Hofvander, Director Investor Relations & Communications  
Phone +46 46 286 44 95  
E-mail: [cecilia.hofvander@alligatorbioscience.com](mailto:cecilia.hofvander@alligatorbioscience.com).

*The information was submitted for publication, through the agency of the contact person set out above, at 1:30 p.m. CET on 21 November 2017.*

### **About Alligator Bioscience**

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527) and novel research candidates. ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees. For more information, please visit [www.alligatorbioscience.com](http://www.alligatorbioscience.com).